Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Ovarian Cancer

Ovarian Cancer

15 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Ovarian Cancer

371 trials tracked for Ovarian Cancer: 43 in phase 3 or 4 and 21 with published results. The most-cited published study has 410 citations.

371Trials tracked
43Phase 3 & 4
0Recruiting
21With published results
Phase distribution
Phase 4 8 Phase 3 35 Phase 2 256 Phase 1 39 Other / NA 33
  1. Phase 3 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed · 410 cited
  2. Phase 3 A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) Completed · 408 cited
  3. Phase 3 Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments Completed · 297 cited
  4. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer Completed · 295 cited
  5. Phase 3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed · 258 cited
  6. Phase 3 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed · 234 cited
Show 44 more trials
  1. Phase 3 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Completed · 225 cited
  2. Phase 3 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed · 194 cited
  3. Phase 3 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed · 193 cited
  4. Phase 3 OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer Completed · 168 cited
  5. Phase 3 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Completed · 143 cited
  6. Phase 3 Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) Completed · 130 cited
  7. Phase 4 Tumor Gene Expression in Women With Ovarian Cancer Completed · 91 cited
  8. Phase 3 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed · 72 cited
  9. Phase 3 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed · 70 cited
  10. Phase 3 Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients Completed · 64 cited
  11. Phase 3 Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients Completed · 57 cited
  12. Phase 3 A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed · 43 cited
  13. Phase 3 Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors Completed · 24 cited
  14. Phase 3 Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) Completed · 18 cited
  15. Phase 3 A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed · 18 cited
  16. Phase 4 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Completed
  17. Phase 4 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed
  18. Phase 4 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Completed
  19. Phase 4 Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer Completed
  20. Phase 4 A Study of Serum Folate Levels in Patients Treated With Olaparib Completed
  21. Phase 4 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed
  22. Phase 4 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed
  23. Phase 3 Accelerating Gastrointestinal Recovery Completed
  24. Phase 3 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed
  25. Phase 3 CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib Completed
  26. Phase 3 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Completed
  27. Phase 3 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed
  28. Phase 3 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed
  29. Phase 3 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  30. Phase 3 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Completed
  31. Phase 3 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed
  32. Phase 3 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Completed
  33. Phase 3 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed
  34. Phase 3 LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer Completed
  35. Phase 3 Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed
  36. Phase 3 Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed
  37. Phase 3 An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer Completed
  38. Phase 2 RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  39. Phase 2 A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone Completed
  40. Phase 2 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Completed
  41. Phase 2 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed
  42. Phase 2 Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors Completed
  43. Phase 2 Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer Completed
  44. Phase 2 Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis Completed

Showing the 50 most-cited and recently-updated of 371 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Ovarian Cancer: what the trials found

Mirvetuximab soravtansine has demonstrated clinical activity in ovarian cancer, with reported CA-125 confirmed clinical response rates of 74.5% 5 and objective response rates (ORR) of 22% compared to 12% in a separate trial 20.

Olaparib is established as an intervention for this condition, showing significant improvements in progression-free survival (PFS) with a median of 13.4 months versus 9.2 months (p=0.013) and a superior objective response rate (ORR) of 109% vs 37% (p=0.002) 19. Clinical assessments of quality of life using FACT-O, FACIT-F, and FLIE scales were also recorded for Olaparib 14.

Paclitaxel has been evaluated in large-scale trials; while it showed a statistically significant improvement in progression-free survival specifically within the PD-L1-positive subpopulation (p=0.0376), there was no significant difference in overall survival for the intent-to-treat population 17.

Other established interventions include bevacizumab, which showed comparable median progression-free survival across study arms (p=0.341) 22, and sodium thiosulfate 21. Additional supportive or adjunctive treatments include dexamethasone 9, aspirin 12, fosaprepitant 15, and pegylated liposomal doxorubicin hydrochloride 16.

Tranexamic acid was shown to significantly reduce perioperative bleeding volume (p=0.03) 13. Regarding monitoring, folic acid supplementation is noted in the context of Olaparib use, where some patients developed folate deficiency or decreased hemoglobin levels 10.

Recent results — preliminary, needs further review

  • Pembrolizumab showed a 95% progression-free survival rate at 6 months when measured from the start of pre-trial weekly paclitaxel, compared to 5.0% for maintenance pembrolizumab alone 2.
  • Metformin hydrochloride did not show statistically significant differences in progression-free survival (p=0.31), time to CA-125/radiological progression (p=0.89), or overall survival (p=0.21) 3.
  • Other emerging interventions include NT-I7 4, Pegylated Liposomal Doxorubicin + SL-172154 6, High-Purity Type-I Collagen Scaffold 7, and Acupressure 8.

For the clinician treating this condition

  • Mirvetuximab soravtansine shows significant clinical response rates in patients with ovarian cancer [5, 20].
  • Olaparib provides a statistically significant improvement in progression-free survival and objective response rates compared to standard controls 19.
  • Tranexamic acid is effective in reducing perioperative bleeding volume 13.
  • Paclitaxel shows specific efficacy in the PD-L1-positive subpopulation 17.

AI synthesis of 19 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Olaparib, rucaparib, and niraparib significantly improve progression-free survival across age groups in advanced ovarian cancer
Oncology Meta-analysis
Olaparib, rucaparib, and niraparib significantly improve progression-free survival across age groups in advanced ovarian cancer PARP Inhibitors Show Improved Survival for Advanced Ovarian Cancer
This network meta-analysis of randomized trials evaluates PARP inhibitors for advanced ovarian cancer. The analysis indicates that olaparib,…
New data shows PARP inhibitors like olaparib and niraparib may improve survival for both younger and older patients with advanced ovarian ca…
Frontiers Jul 9, 2026
Sugar sweetened beverages and orange juice are associated with increased risk of several cancer types
Nutrition & Obesity Medicine Sys. Review
Sugar sweetened beverages and orange juice are associated with increased risk of several cancer types Sugar sweetened drinks may increase risk of several cancer types
This meta-analysis of 51 cohort studies evaluates the link between sugar sweetened beverages (SSBs), artificially sweetened beverages (ASBs)…
New research suggests a link between sugar-sweetened beverages and an increased risk of certain cancers, including pancreatic and colorectal…
medRxiv Jul 7, 2026
Radiomics and clinical data combined in AI models achieve 0.86 AUC for predicting ovarian cancer metastasis
Radiology & Imaging Meta-analysis
Radiomics and clinical data combined in AI models achieve 0.86 AUC for predicting ovarian cancer metastasis Artificial intelligence helps predict where ovarian cancer has spread
This systematic review and meta-analysis analyzed medical image-based artificial intelligence models for predicting metastasis in patients w…
New analysis shows that AI models combining medical images and patient data can accurately predict if ovarian cancer has spread to other org…
Jul 6, 2026
NLRP3 inflammasome modulates immune evasion and chemotherapy sensitivity in gynecological cancers
Allergy & Immunology Sys. Review
NLRP3 inflammasome modulates immune evasion and chemotherapy sensitivity in gynecological cancers New research identifies a key driver in gynecological cancer cells
This mini-review examines the role of the NLRP3 inflammasome in ovarian, endometrial, and cervical cancers. It highlights how NLRP3 impacts …
A protein called NLRP3 helps certain cancers hide from the immune system, but it also plays a complex role in how tumors react to treatment.
Frontiers Jun 24, 2026
Glycolysis-centered understanding of ovarian cancer may support biomarker-guided combination strategies and improve translational therapeutic design
Allergy & Immunology Sys. Review
Glycolysis-centered understanding of ovarian cancer may support biomarker-guided combination strategies and improve translational therapeutic design New review suggests metabolic pathways in ovarian cancer need better tools to treat
This narrative review explores glycolysis-centered understanding of ovarian cancer. The authors suggest this perspective may support biomark…
A fresh look at ovarian cancer metabolism shows current tools are too limited to guide effective combination therapies for patients.
Frontiers Jun 3, 2026
Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer
Allergy & Immunology Sys. Review
Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer New immune targets offer hope for ovarian cancer patients
This narrative review synthesizes evidence on follicular T cell subsets, tertiary lymphoid structures, and other immune features in ovarian …
A review highlights new immune system features that could help doctors predict treatment success and find better ways to fight ovarian cance…
Frontiers Jun 2, 2026
Review of ovarian cancer treatments including olaparib, bevacizumab, and durvalumab discusses limitations and biomarkers
Allergy & Immunology Sys. Review
Review of ovarian cancer treatments including olaparib, bevacizumab, and durvalumab discusses limitations and biomarkers New drug combos target hidden cancer switches to stop resistance
This narrative review examines ovarian cancer management involving olaparib, bevacizumab, and durvalumab.
Hidden chemical changes in ovarian cancer cells help them hide from drugs, but new combinations might finally stop them from adapting and gr…
Frontiers May 1, 2026
Narrative review on precision prevention for women with inherited gynecologic cancer susceptibility
Oncology Sys. Review
Narrative review on precision prevention for women with inherited gynecologic cancer susceptibility New Plan Cuts Cancer Risk for High-Risk Women
This narrative review addresses ovarian, endometrial, and fallopian tube cancer in women with inherited gynecologic cancer susceptibility.
Women with strong family histories of ovarian or uterine cancer can now take smarter, personalized steps to reduce their risk — and it’s cha…
Frontiers Apr 28, 2026
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
Oncology RCT
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
Apr 23, 2026
Narrative review links microbiome dysbiosis to gynecological cancer pathogenesis and potential therapeutic applications
OB/GYN & Women's Health Sys. Review
Narrative review links microbiome dysbiosis to gynecological cancer pathogenesis and potential therapeutic applications Microbiome changes may help explain how gynecological cancers start and grow
This narrative review examines the role of the human microbiome in gynecological malignancies, including cervical, ovarian, endometrial, vul…
New review suggests microbiome shifts could be key to understanding gynecological cancers, opening doors for better prevention and treatment…
Frontiers Apr 23, 2026
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer
Oncology RCT
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer New Drug Combo Extends Survival for Tough Ovarian Cancer Cases
In a phase 3 randomised controlled trial of 381 patients with platinum-resistant ovarian cancer, relacorilant plus nab-paclitaxel significan…
This combination offers a new, simpler option for patients who have run out of standard treatments.
Apr 20, 2026
Meta-analysis of 11 cohort studies finds oral contraceptives associated with reduced ovarian cancer incidence
Drug Pipeline Meta-analysis
Meta-analysis of 11 cohort studies finds oral contraceptives associated with reduced ovarian cancer incidence Birth Control Pills Cut Ovarian Cancer Risk — But Only If Used This Long
This meta-analysis of 11 cohort studies evaluated oral contraceptives and ovarian cancer incidence across multiple databases.
Using birth control pills for more than five years lowers ovarian cancer risk, offering a simple way to protect women from this deadly disea…
Frontiers Apr 18, 2026

Questions about Ovarian Cancer

Is [68Ga]Ga-FAPI PET imaging accurate for diagnosing Ovarian Cancer?

Yes, [68Ga]Ga-FAPI PET imaging is highly accurate for diagnosing ovarian cancer, especially for detecting peritoneal and lymph node metastases, and may outperform standard FDG PET in certain settings.

Full answer →
Do PARP inhibitors improve survival for patients with BRCA-mutated Ovarian Cancer?

Yes, PARP inhibitors significantly improve progression-free survival for patients with BRCA-mutated ovarian cancer, with some studies also showing overall survival benefits.

Full answer →
Can relacorilant and nab-paclitaxel help patients with platinum-resistant Ovarian Cancer?

Yes, relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer, based on phase 2 and phase 3 trial results.

Full answer →
Does taking birth control pills lower the risk of getting Ovarian Cancer?

Yes, taking birth control pills is associated with a lower risk of ovarian cancer, especially with longer use.

Full answer →

All Ovarian Cancer Articles